Skip to main content

Menu

BNF February 2023 Update


This update contains 3 significant changes, 1 dose change, and 3 new monographs.Significant Changes:

  • Dupilumab (Dupixent®): risk of ocular adverse reactions and need for prompt management [MHRA/CHM advice] (advice in dupilumab and tralokinumab; see example in dupilumab).
  • Ibuprofen: updated breast-feeding advice.
  • Obesity: updated guidance on management.Dose Change:
  • Ibuprofen [update to dosing for acute moderate pain]New Monographs:
  • Aethoxysklerol® [lauromacrogol 400]
  • Crysvita® [burosumab]
  • Mounjaro® [tirzepatide]